These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 22607893)

  • 1. Development of a vaccine against serogroup B has been the main scientific challenge. Preface.
    Rappuoli R; Pizza M; Black S; Moxon ER
    Vaccine; 2012 May; 30 Suppl 2():B1-2. PubMed ID: 22607893
    [No Abstract]   [Full Text] [Related]  

  • 2. Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease.
    Dull PM; McIntosh ED
    Vaccine; 2012 May; 30 Suppl 2():B18-25. PubMed ID: 22607895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The challenge of post-implementation surveillance for novel meningococcal vaccines.
    Snape MD; Medini D; Halperin SA; DeTora L; Drori J; Moxon ER
    Vaccine; 2012 May; 30 Suppl 2():B67-72. PubMed ID: 22230578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease, Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Vaccine 2007;25(16):3080-4.
    Lennon D
    Vaccine; 2007 Sep; 25(39-40):6833; author reply 6833-4. PubMed ID: 17630051
    [No Abstract]   [Full Text] [Related]  

  • 5. History of meningococcal vaccines and their serological correlates of protection.
    Vipond C; Care R; Feavers IM
    Vaccine; 2012 May; 30 Suppl 2():B10-7. PubMed ID: 22607894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Group B meningococcal invasive infections: an unresolved public health problem].
    Crisinel PA; Posfay-Barbe KM
    Rev Med Suisse; 2011 Feb; 7(283):447-50. PubMed ID: 21452513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MenB candidate vaccine Bexsero induces robust immune response in infants.
    Riedmann EM
    Hum Vaccin Immunother; 2012 Mar; 8(3):282. PubMed ID: 23213659
    [No Abstract]   [Full Text] [Related]  

  • 8. Pfizer’s men B vaccine shows promise in phase 2.
    Hum Vaccin Immunother; 2012 Aug; 8(8):1016-7. PubMed ID: 23359878
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks.
    Taha MK; Zarantonelli ML; Alonso JM; Naess LM; Holst J; Feiring B; Rosenqvist E
    Vaccine; 2007 Mar; 25(14):2537-8. PubMed ID: 16460845
    [No Abstract]   [Full Text] [Related]  

  • 10. Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine.
    Esposito S; Principi N
    Expert Rev Vaccines; 2014 Feb; 13(2):193-202. PubMed ID: 24393061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.
    Su EL; Snape MD
    Expert Rev Vaccines; 2011 May; 10(5):575-88. PubMed ID: 21604979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Group B meningococcal vaccine science and policy.
    Drysdale SB; Pollard AJ
    J Infect; 2015 Jun; 71 Suppl 1():S15-20. PubMed ID: 25917798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?
    Martin NG; Snape MD
    Expert Rev Vaccines; 2013 Aug; 12(8):837-58. PubMed ID: 23984957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New frontiers in meningococcal vaccines.
    Anderson AS; Jansen KU; Eiden J
    Expert Rev Vaccines; 2011 May; 10(5):617-34. PubMed ID: 21604983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Meningococcal serogroup B vaccines].
    Dommergues MA
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S65-9. PubMed ID: 22883369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent developments in vaccines to prevent meningococcal serogroup B infections.
    Vermont CL; van den Dobbelsteen GP; de Groot R
    Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two meningococcal B vaccines receive FDA 'breakthrough therapy' designation.
    Riedmann EM
    Hum Vaccin Immunother; 2014; 10(6):1428-9. PubMed ID: 25396230
    [No Abstract]   [Full Text] [Related]  

  • 18. Challenges and progress in the development of a serogroup B meningococcal vaccine.
    Lewis S; Sadarangani M; Hoe JC; Pollard AJ
    Expert Rev Vaccines; 2009 Jun; 8(6):729-45. PubMed ID: 19485754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Commentary: European Medicines Agency recommends approval of a broadly protective vaccine against serogroup B meningococcal disease.
    Granoff DM
    Pediatr Infect Dis J; 2013 Apr; 32(4):372-3. PubMed ID: 23263177
    [No Abstract]   [Full Text] [Related]  

  • 20. Meningococcal serogroup B vaccines: will they live up to expectations?
    Zollinger WD; Poolman JT; Maiden MC
    Expert Rev Vaccines; 2011 May; 10(5):559-61. PubMed ID: 21604975
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.